Jane Street Group LLC Takes $251,000 Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Jane Street Group LLC acquired a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 13,354 shares of the company’s stock, valued at approximately $251,000. Jane Street Group LLC owned 0.09% of Jasper Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Samsara BioCapital LLC raised its stake in shares of Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after purchasing an additional 59,642 shares during the period. Braidwell LP acquired a new stake in shares of Jasper Therapeutics during the third quarter worth approximately $9,091,000. Ally Bridge Group NY LLC grew its position in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after buying an additional 180,852 shares in the last quarter. State Street Corp grew its position in shares of Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after buying an additional 23,564 shares in the last quarter. Finally, Fernwood Investment Management LLC grew its position in shares of Jasper Therapeutics by 6.9% during the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after buying an additional 3,427 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

JSPR stock opened at $7.05 on Friday. The stock has a market capitalization of $105.76 million, a price-to-earnings ratio of -1.49 and a beta of 2.18. Jasper Therapeutics, Inc. has a 1 year low of $6.57 and a 1 year high of $31.01. The stock’s fifty day moving average is $21.09 and its two-hundred day moving average is $20.16.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. Royal Bank of Canada decreased their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday. HC Wainwright decreased their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics has a consensus rating of “Buy” and a consensus target price of $67.75.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.